Pathogenic variants in the X-linked gene NEXMIF (previously KIAA2022) are associated with intellectual disability (ID), autism spectrum disorder, and epilepsy. We aimed to delineate the female and male phenotypic spectrum of NEXMIF encephalopathy.
Through an international collaboration, we analyzed the phenotypes and genotypes of 87 patients with NEXMIF encephalopathy.
Sixty-three females and 24 males (46 new patients) with NEXMIF encephalopathy were studied, with 30 novel variants. Phenotypic features included developmental delay/ID in 86/87 (99%), seizures in 71/86 (83%) and multiple comorbidities. Generalized seizures predominated including myoclonic seizures and absence seizures (both 46/70, 66%), absence with eyelid myoclonia (17/70, 24%), and atonic seizures (30/70, 43%). Males had more severe developmental impairment; females had epilepsy more frequently, and varied from unaffected to severely affected. All NEXMIF pathogenic variants led to a premature stop codon or were deleterious structural variants. Most arose de novo, although X-linked segregation occurred for both sexes. Somatic mosaicism occurred in two males and a family with suspected parental mosaicism.
NEXMIF encephalopathy is an X-linked, generalized developmental and epileptic encephalopathy characterized by myoclonic–atonic epilepsy overlapping with eyelid myoclonia with absence. Some patients have developmental encephalopathy without epilepsy. Males have more severe developmental impairment. NEXMIF encephalopathy arises due to loss-of-function variants.
Subscribe to Journal
Get full journal access for 1 year
only $41.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58:512–521.
Howell KB, Eggers S, Dalziel K, et al. A population-based cost-effectiveness study of early genetic testing in severe epilepsies of infancy. Epilepsia. 2018;59:1177–1187.
Heyne HO, Singh T, Stamberger H, et al. De novo variants in neurodevelopmental disorders with epilepsy. Nat Genet. 2018;50:1048–1053.
Dibbens LM, Tarpey PS, Hynes K, et al. X-linked protocadherin 19 mutations cause female-limited epilepsy and cognitive impairment. Nat Genet. 2008;40:776–781.
Mignot C, McMahon AC, Bar C, et al. IQSEC2-related encephalopathy in males and females: a comparative study including 37 novel patients. Genet Med. 2019;21:837–849.
Migeon BR. The role of X inactivation and cellular mosaicism in women’s health and sex-specific diseases. JAMA. 2006;295:1428–1433.
Plenge RM, Stevenson RA, Lubs HA, Schwartz CE, Willard HF. Skewed X-chromosome inactivation is a common feature of X-linked mental retardation disorders. Am J Hum Genet. 2002;71:168–173.
Gilbert J, Man HY. The X-linked autism protein KIAA2022/KIDLIA regulates neurite outgrowth via N-cadherin and delta-catenin signaling. eNeuro. 2016;3:ENEURO.0238-16.2016.
Magome T, Hattori T, Taniguchi M, et al. XLMR protein related to neurite extension (Xpn/KIAA2022) regulates cell–cell and cell-matrix adhesion and migration. Neurochem Int. 2013;63:561–569.
Ishikawa T, Miyata S, Koyama Y, et al. Transient expression of Xpn, an XLMR protein related to neurite extension, during brain development and participation in neurite outgrowth. Neuroscience. 2012;214:181–191.
Gilbert J, O’Connor M, Templet S, et al. NEXMIF/KIDLIA knock-out mouse demonstrates autism-like behaviors, memory deficits, and impairments in synapse formation and function. J Neurosci. 2020;40:237–254.
Cantagrel V, Lossi AM, Boulanger S, et al. Disruption of a new X linked gene highly expressed in brain in a family with two mentally retarded males. J Med Genet. 2004;41:736–742.
Van Maldergem L, Hou Q, Kalscheuer VM, et al. Loss of function of KIAA2022 causes mild to severe intellectual disability with an autism spectrum disorder and impairs neurite outgrowth. Hum Mol Genet. 2013;22:3306–3314.
Athanasakis E, Licastro D, Faletra F, et al. Next generation sequencing in nonsyndromic intellectual disability: from a negative molecular karyotype to a possible causative mutation detection. Am J Med Genet A. 2014;164A:170–176.
Moyses-Oliveira M, Guilherme RS, Meloni VA, et al. X-linked intellectual disability related genes disrupted by balanced X-autosome translocations. Am J Med Genet B Neuropsychiatr Genet. 2015;168:669–677.
Farach LS, Northrup H. KIAA2022 nonsense mutation in a symptomatic female. Am J Med Genet A. 2016;170:703–706.
de Lange IM, Helbig KL, Weckhuysen S, et al. De novo mutations of KIAA2022 in females cause intellectual disability and intractable epilepsy. J Med Genet. 2016;53:850–858.
Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58:522–530.
Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-9. Epilepsia. 2010;51:676–685.
Samanta D, Willis E. KIAA2022-related disorders can cause Jeavons (eyelid myoclonia with absence) syndrome. Acta Neurol Belg. 2020;120:205–207.
Kuroda Y, Ohashi I, Naruto T, et al. Delineation of the KIAA2022 mutation phenotype: two patients with X-linked intellectual disability and distinctive features. Am J Med Genet A. 2015;167:1349–1353.
Webster R, Cho MT, Retterer K, et al. De novo loss of function mutations in KIAA2022 are associated with epilepsy and neurodevelopmental delay in females. Clin Genet. 2017;91:756–763.
Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–424.
Lek M, Karczewski KJ, Minikel EV, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536:285–291.
Charzewska A, Rzonca S, Janeczko M. et al. A duplication of the whole KIAA2022 gene validates the gene role in the pathogenesis of intellectual disability and autism. Clin Genet. 2015;88:297–299.
Borlot F, Regan BM, Bassett AS, Stavropoulos DJ, Andrade DM. Prevalence of pathogenic copy number variation in adults with pediatric-onset epilepsy and intellectual disability. JAMA Neurol. 2017;74:1301–1311.
Lorenzo M, Stolte-Dijkstra I, van Rheenen P, Smith RG, Scheers T, Walia JS. Clinical spectrum of KIAA2022 pathogenic variants in males: case report of two boys with KIAA2022 pathogenic variants and review of the literature. Am J Med Genet A. 2018;176:1455–1462.
Lambert N, Dauve C, Ranza E, et al. Novel NEXMIF pathogenic variant in a boy with severe autistic features, intellectual disability, and epilepsy, and his mildly affected mother. J Hum Genet. 2018;63:847–850.
Myers CT, Hollingsworth G, Muir AM, et al. Parental mosaicism in “de novo” epileptic encephalopathies. N Engl J Med. 2018;378:1646–1648.
Alarcon-Martinez T, Khan A, Myers KA. Torpedo maculopathy associated with NEXMIF mutation. Mol Syndromol. 2019;10:229–233.
Gurovich Y, Hanani Y, Bar O, et al. Identifying facial phenotypes of genetic disorders using deep learning. Nat Med. 2019;25:60–64.
Caraballo RH, Fontana E, Darra F, et al. A study of 63 cases with eyelid myoclonia with or without absences: type of seizure or an epileptic syndrome? Seizure. 2009;18:440–445.
Vlaskamp DRM, Shaw BJ, Burgess R, et al. SYNGAP1 encephalopathy: a distinctive generalized developmental and epileptic encephalopathy. Neurology. 2019;92:e96–e107.
Rubboli G, Gardella E, Capovilla G. Idiopathic generalized epilepsy (IGE) syndromes in development: IGE with absences of early childhood, IGE with phantom absences, and perioral myoclonia with absences. Epilepsia. 2009;50 Suppl 5:24–28.
Vaudano AE, Ruggieri A, Tondelli M, et al. The visual system in eyelid myoclonia with absences. Ann Neurol. 2014;76:412–427.
Thomas RH, Zhang LM, Carvill GL, et al. CHD2 myoclonic encephalopathy is frequently associated with self-induced seizures. Neurology. 2015;84:951–958.
Johannesen KM, Gardella E, Linnankivi T, et al. Defining the phenotypic spectrum of SLC6A1 mutations. Epilepsia. 2018;59:389–402.
Thomas GH. High male:female ratio of germ-line mutations: an alternative explanation for postulated gestational lethality in males in X-linked dominant disorders. Am J Hum Genet. 1996;58:1364–1368.
Girard M, Couvert P, Carrie A, et al. Parental origin of de novo MECP2 mutations in Rett syndrome. Eur J Hum Genet. 2001;9:231–236.
Carrette LLG, Wang CY, Wei C, et al. A mixed modality approach towards Xi reactivation for Rett syndrome and other X-linked disorders. Proc Natl Acad Sci U S A. 2018;115:E668–E675.
We thank the patients and their families for participating in our research. We further want to acknowledge the Epi25 Consortium for providing a platform for exome sequencing for epilepsy patients that led to a diagnosis for some of the patients included in this study. H.S. was PhD fellow of the Fund for Scientific Research Flanders (1125416N). H.C.M. received support from the National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) (R01NS069605). D.M.A. received funding from EpLink, of the Ontario Brain Institute for array comparative genomic hybridization (aCGH) analysis. This study was supported by the Key Research Project of the Ministry of Science and Technology of China (2016YFC0904400 and 2016YFC0904401; through J.Z. and Y.A.Z.), Cure Kids New Zealand (through L.G.S.) and the Victorian Government’s Operational Infrastructure Support Program and the Australian Government National Health and Medical Research Council (NHMRC) Independent Medical Research Institutes Infrastructure Support Scheme (IRIISS) (through M.B.). The work was generated within ITHACA (Intellectual disability, TeleHealth, And Congenital Anomalies), European Reference Network on Rare Congenital Malformations, and Rare Intellectual Disability.
R.G. has acted as an investigator for studies with Zogenix, Biocodex, Biomarin, UCB, Angelini, and Eisai Inc. He has been a speaker and on advisory boards for Zogenix, Biocodex, Novartis, Biomarin, GW Pharma, and Biocodex; serves/has served on the editorial boards of Epilepsia, Progress in Epileptic Disorders, Neuropediatrics, Journal of Child Neurology, Seizure, BMC Medical Genetics, Topics in Epilepsy, and Neurology. He receives/has received research support from the Italian Ministry of Health, The European Community, The Tuscany Region, the Mariani Foundation, The Pisa Foundation, The Fund of Epilepsy, The GKT Special Trustees, The Italian Federation for Epilepsy, and The Italian Association for Epilepsy. I.E.S. serves/has served on the editorial boards of the Annals of Neurology, Neurology, and Epileptic Disorders; may accrue future revenue on pending patent WO61/010176 (filed: 2008): Therapeutic Compound; has a patent for SCN1A testing held by Bionomics, Inc., and licensed to various diagnostic companies; has a patent molecular diagnostic/theranostic target for benign familial infantile epilepsy (BFIE) [PRRT2] 2011904493 & 2012900190 and PCT/AU2012/001321 (TECH ID:2012-009) with royalties paid. She has served on scientific advisory boards for UCB, Eisai, GlaxoSmithKline, BioMarin, Nutricia, Rogcon, and Xenon Pharmaceuticals; has received speaker honoraria from GlaxoSmithKline, UCB, BioMarin, Biocodex, and Eisai; has received funding for travel from UCB, Biocodex, GlaxoSmithKline, Biomarin, and Eisai; has served as an investigator for Zogenix, Zynerba, Ultragenyx, GW Pharma, UCB, Eisai, Anavex Life Scienand Marinus; and has consulted for Zynerba Pharmaceuticals, Atheneum Partners, Ovid Therapeutics, and UCB. She receives/has received research support from the National Health and Medical Research Council of Australia, Health Research Council of New Zealand, CURE, Australian Epilepsy Research Fund, March of Dimes and NIH/NINDS. D.M.A. has consulted for Eisai, UCB, and is part of the MAB of Stoke Therapeutics and DSF. B.G. has received consultancy fees from GW Pharmaceuticals companies, Zogenix, and Ovid/Takeda; and is a principal investigator for GW Research Ltd, Zogenix, LivaNova, Marinus Pharmaceuticals, and UCB. L.G.S. reports grants from Health Research Council of New Zealand, grants from Cure Kids New Zealand, during the conduct of the study; grants and personal fees from Zynerba, other from Sequirus, other from Nutricia, outside the submitted work. S.M.Z. has received research funding from Epilepsy Research UK, UCB Pharma, Glasgow Children’s Hospital Charity, Dravet Syndrome UK. He serves as Editor-in-Chief of European Journal of Pediatric Neurology for which he receives an honorarium from Elsevier Ltd. He has participated in educational symposia/advisory boards/consulted for GW Pharma, Zogenix Ltd, Biocodex, Nutricia, and Encoded Genomics. The other authors declare no conflicts of interest.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Stamberger, H., Hammer, T.B., Gardella, E. et al. NEXMIF encephalopathy: an X-linked disorder with male and female phenotypic patterns. Genet Med (2020). https://doi.org/10.1038/s41436-020-00988-9
- developmental and epileptic encephalopathy
- intellectual disability